We have recently seen the publication of a posthoc analysis of lung cancer deaths in women
taking estrogen and a progestin1. Among the 16608 women recruited into the combined …

ASECONDARY ANALYSIS FROM THE Women's Health Initiative has found that past use of
hormone therapy with estrogen plus progestin increases the risk of dying from non–small …

The Women's Heath Initiative (WHI) trial was a double-blind randomised placebo-controlled
trial that examined the health benefits and risks of combined oestrogen and progestin in …

Abstract Introduction In the Women's Health Initiative (WHI) estrogen plus progestin trial,
after 5.6 years' intervention and 8 years' median follow-up, more women died from lung …

Abstract BACKGROUND: The Women's Health Initiative randomized clinical trial reported
that menopausal hormone therapy increases lung cancer mortality risk. If this is true, use of …

ORLANDO—Hormone therapy with estrogen plus progestin for more than 5 years increased
the risk of death in women diagnosed with non–small cell lung cancer, based on secondary …

SA N ANTONIO—Women treated with anti-estrogen therapy for breast cancer appeared to
have a reduced risk of dying later from lung cancer in a Swiss registry study, suggesting that …

Since 2008 the Women's Health Initiative (WHI) investigators have published a series of
reports on the risk of lung cancer in users of menopausal hormones containing estrogen …

Introduction: Results from the Women's Health Initiative clinical trials demonstrated no
increase in the risk of lung cancer in postmenopausal women treated with hormone therapy …

Abstract Background In the Women's Health Initiative (WHI) randomized controlled trial, use
of estrogen plus progestin increased lung cancer mortality. We conducted post hoc analyses …